Media coverage about iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) has been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. iShares Nasdaq Biotechnology Index Fund earned a news impact score of 0.17 on Accern’s scale. Accern also assigned media headlines about the financial services provider an impact score of 46.1860431712772 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the media headlines that may have impacted Accern’s rankings:

Separately, Vetr lowered shares of iShares Nasdaq Biotechnology Index Fund from a “buy” rating to a “hold” rating and set a $307.00 target price on the stock. in a report on Monday, June 5th.

Shares of iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) opened at 331.82 on Friday. The firm has a 50-day moving average of $319.37 and a 200 day moving average of $304.37. iShares Nasdaq Biotechnology Index Fund has a 12-month low of $246.71 and a 12-month high of $336.72.

COPYRIGHT VIOLATION WARNING: “iShares Nasdaq Biotechnology Index Fund (IBB) Getting Somewhat Favorable Media Coverage, Accern Reports” was first published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dailypolitical.com/2017/09/16/ishares-nasdaq-biotechnology-index-fund-ibb-getting-somewhat-favorable-media-coverage-accern-reports.html.

About iShares Nasdaq Biotechnology Index Fund

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Insider Buying and Selling by Quarter for iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology Index Fund Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology Index Fund and related companies with MarketBeat.com's FREE daily email newsletter.